Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. More Details
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Antisense Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ANP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ANP's weekly volatility has decreased from 18% to 11% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ANP exceeded the Australian Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: ANP exceeded the Australian Market which returned 37.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Antisense Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWe Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
5 months ago | Simply Wall StWill Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?
11 months ago | Simply Wall StAntisense Therapeutics (ASX:ANP) Shareholders Booked A 55% Gain In The Last Three Years
Is Antisense Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ANP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ANP is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: ANP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANP is overvalued based on its PB Ratio (9.7x) compared to the AU Pharmaceuticals industry average (3.3x).
How is Antisense Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANP's revenue is expected to decline over the next 3 years (-39.3% per year).
High Growth Revenue: ANP's revenue is forecast to decline over the next 3 years (-39.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANP is forecast to be unprofitable in 3 years.
How has Antisense Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANP is currently unprofitable.
Growing Profit Margin: ANP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANP is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare ANP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.5%).
Return on Equity
High ROE: ANP has a negative Return on Equity (-34.95%), as it is currently unprofitable.
How is Antisense Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ANP's short term assets (A$11.0M) exceed its short term liabilities (A$744.9K).
Long Term Liabilities: ANP's short term assets (A$11.0M) exceed its long term liabilities (A$254.6K).
Debt to Equity History and Analysis
Debt Level: ANP is debt free.
Reducing Debt: ANP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANP has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 24.9% each year.
What is Antisense Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ANP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Mark Diamond, BSc, MBA, MAICD, has been the Chief Executive Officer and Managing Director of Antisense Therapeutics Ltd. since October 31, 2001. Mr. Diamond has broad international experience in busine...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD936.10K) is above average for companies of similar size in the Australian market ($USD287.37K).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Experienced Management: ANP's management team is seasoned and experienced (14.5 years average tenure).
Experienced Board: ANP's board of directors are seasoned and experienced ( 12.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.4%.
Antisense Therapeutics Limited's company bio, employee growth, exchange listings and data sources
- Name: Antisense Therapeutics Limited
- Ticker: ANP
- Exchange: ASX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$106.200m
- Shares outstanding: 574.06m
- Website: https://www.antisense.com.au
Number of Employees
- Antisense Therapeutics Limited
- 14 Wallace Avenue
- Level 1
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense in...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 08:25|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.